Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: MK0677

Study type: Interventional

Funder types: Industry

Identifiers

NCT00074529

0677-030

2006_412

MK0677-030

Formally-BG0812AZ

Details and patient eligibility

About

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Enrollment: 512 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Patients must have probable Alzheimer's disease of mild or moderate severity.
• A brain scan and laboratory results must be consistent with Alzheimer's disease.
• The patient must be otherwise medically healthy.